121 related articles for article (PubMed ID: 30259936)
1. Arsenic trioxide preferentially binds to the ring finger protein PML: understanding target selection of the drug.
Kaiming C; Sheng Y; Zheng S; Yuan S; Huang G; Liu Y
Metallomics; 2018 Nov; 10(11):1564-1569. PubMed ID: 30259936
[TBL] [Abstract][Full Text] [Related]
2. Integrity of zinc finger motifs in PML protein is necessary for inducing its degradation by antimony.
Yang C; Hao R; Lan YF; Chen YJ; Wang C; Bu N; Wang QQ; Hussain L; Ma LY; Maimaitiyiming Y; Lu XY; Naranmandura H
Metallomics; 2019 Aug; 11(8):1419-1429. PubMed ID: 31313788
[TBL] [Abstract][Full Text] [Related]
3. Role of PML SUMOylation in arsenic trioxide-induced fibrosis in HSCs.
Dai J; Hu Y; Niu Q; Song G; Wang H; Li S
Life Sci; 2020 Jun; 251():117607. PubMed ID: 32240679
[TBL] [Abstract][Full Text] [Related]
4. Sumoylation of the Tumor Suppressor Promyelocytic Leukemia Protein Regulates Arsenic Trioxide-Induced Collagen Synthesis in Osteoblasts.
Xu WX; Liu SZ; Wu D; Qiao GF; Yan J
Cell Physiol Biochem; 2015; 37(4):1581-91. PubMed ID: 26517826
[TBL] [Abstract][Full Text] [Related]
5. JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML.
Dagher T; Maslah N; Edmond V; Cassinat B; Vainchenker W; Giraudier S; Pasquier F; Verger E; Niwa-Kawakita M; Lallemand-Breitenbach V; Plo I; Kiladjian JJ; Villeval JL; de Thé H
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33075130
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.
Zhang XW; Yan XJ; Zhou ZR; Yang FF; Wu ZY; Sun HB; Liang WX; Song AX; Lallemand-Breitenbach V; Jeanne M; Zhang QY; Yang HY; Huang QH; Zhou GB; Tong JH; Zhang Y; Wu JH; Hu HY; de Thé H; Chen SJ; Chen Z
Science; 2010 Apr; 328(5975):240-3. PubMed ID: 20378816
[TBL] [Abstract][Full Text] [Related]
7. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Zhang X; Yang XR; Sun C; Hu B; Sun YF; Huang XW; Wang Z; He YF; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J
Cancer Lett; 2015 Sep; 366(1):112-22. PubMed ID: 26118777
[TBL] [Abstract][Full Text] [Related]
8. Multimodal approach to characterize the tetrameric form of human PML-RBCC domain and ATO-mediated conformational changes.
Dubey S; Mishra N; Goswami N; Siddiqui MQ; Varma AK
Int J Biol Macromol; 2022 Dec; 223(Pt A):468-478. PubMed ID: 36356867
[TBL] [Abstract][Full Text] [Related]
9. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
[TBL] [Abstract][Full Text] [Related]
10. Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation.
Wang QQ; Zhou XY; Zhang YF; Bu N; Zhou J; Cao FL; Naranmandura H
Oncotarget; 2015 Sep; 6(28):25646-59. PubMed ID: 26213848
[TBL] [Abstract][Full Text] [Related]
11. Differential binding of monomethylarsonous acid compared to arsenite and arsenic trioxide with zinc finger peptides and proteins.
Zhou X; Sun X; Mobarak C; Gandolfi AJ; Burchiel SW; Hudson LG; Liu KJ
Chem Res Toxicol; 2014 Apr; 27(4):690-8. PubMed ID: 24611629
[TBL] [Abstract][Full Text] [Related]
12. Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia.
Alfonso V; Iaccarino L; Ottone T; Cicconi L; Lavorgna S; Divona M; Cairoli R; Cristiano A; Ciardi C; Travaglini S; Falconi G; Hasan SK; Venditti A; Arcese W; Voso MT; Lo-Coco F
Leukemia; 2019 Jun; 33(6):1527-1530. PubMed ID: 30651632
[No Abstract] [Full Text] [Related]
13. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
Kunapuli P; Kasyapa CS; Chin SF; Caldas C; Cowell JK
Exp Cell Res; 2006 Nov; 312(19):3739-51. PubMed ID: 17027752
[TBL] [Abstract][Full Text] [Related]
14. [Acute promyelocytic leukemia: state-of-the-art management].
Asou N
Rinsho Ketsueki; 2018; 59(6):725-734. PubMed ID: 29973452
[TBL] [Abstract][Full Text] [Related]
15. Dual origin of relapses in retinoic-acid resistant acute promyelocytic leukemia.
Lehmann-Che J; Bally C; Letouzé E; Berthier C; Yuan H; Jollivet F; Ades L; Cassinat B; Hirsch P; Pigneux A; Mozziconacci MJ; Kogan S; Fenaux P; de Thé H
Nat Commun; 2018 May; 9(1):2047. PubMed ID: 29795382
[TBL] [Abstract][Full Text] [Related]
16. Molecular targeting therapy against promyelocytic leukemia protein using arsenic acids in experimental intracranial medulloblastoma.
Gu C; Yokota N; Gao Y; Amano S; Koizumi S; Tokuyama T; Namba H
Neurol Med Chir (Tokyo); 2012; 52(2):62-7. PubMed ID: 22362285
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia.
Xu W; Li X; Quan L; Yao J; Mu G; Guo J; Wang Y
Leuk Lymphoma; 2018 Mar; 59(3):650-659. PubMed ID: 28679299
[TBL] [Abstract][Full Text] [Related]
18. PCGF2 negatively regulates arsenic trioxide-induced PML-RARA protein degradation via UBE2I inhibition in NB4 cells.
Jo S; Lee YL; Kim S; Lee H; Chung H
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt A):1499-509. PubMed ID: 27030546
[TBL] [Abstract][Full Text] [Related]
19. Molecular targets of arsenic trioxide in malignant cells.
Miller WH
Oncologist; 2002; 7 Suppl 1():14-9. PubMed ID: 11961205
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide promoting ETosis in acute promyelocytic leukemia through mTOR-regulated autophagy.
Li T; Ma R; Zhang Y; Mo H; Yang X; Hu S; Wang L; Novakovic VA; Chen H; Kou J; Bi Y; Yu B; Fang S; Wang J; Zhou J; Shi J
Cell Death Dis; 2018 Jan; 9(2):75. PubMed ID: 29362482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
